Cargando…

Pulmonary vascular inflammation with fatal coronavirus disease 2019 (COVID-19): possible role for the NLRP3 inflammasome

BACKGROUND: Pulmonary hyperinflammation is a key event with SARS-CoV-2 infection. Acute respiratory distress syndrome (ARDS) that often accompanies COVID-19 appears to have worse outcomes than ARDS from other causes. To date, numerous lung histological studies in cases of COVID-19 have shown extensi...

Descripción completa

Detalles Bibliográficos
Autores principales: Paul, Oindrila, Tao, Jian Qin, West, Eric, Litzky, Leslie, Feldman, Michael, Montone, Kathleen, Rajapakse, Chamith, Bermudez, Christian, Chatterjee, Shampa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8830114/
https://www.ncbi.nlm.nih.gov/pubmed/35144622
http://dx.doi.org/10.1186/s12931-022-01944-8
_version_ 1784648209599037440
author Paul, Oindrila
Tao, Jian Qin
West, Eric
Litzky, Leslie
Feldman, Michael
Montone, Kathleen
Rajapakse, Chamith
Bermudez, Christian
Chatterjee, Shampa
author_facet Paul, Oindrila
Tao, Jian Qin
West, Eric
Litzky, Leslie
Feldman, Michael
Montone, Kathleen
Rajapakse, Chamith
Bermudez, Christian
Chatterjee, Shampa
author_sort Paul, Oindrila
collection PubMed
description BACKGROUND: Pulmonary hyperinflammation is a key event with SARS-CoV-2 infection. Acute respiratory distress syndrome (ARDS) that often accompanies COVID-19 appears to have worse outcomes than ARDS from other causes. To date, numerous lung histological studies in cases of COVID-19 have shown extensive inflammation and injury, but the extent to which these are a COVID-19 specific, or are an ARDS and/or mechanical ventilation (MV) related phenomenon is not clear. Furthermore, while lung hyperinflammation with ARDS (COVID-19 or from other causes) has been well studied, there is scarce documentation of vascular inflammation in COVID-19 lungs. METHODS: Lung sections from 8 COVID-19 affected and 11 non-COVID-19 subjects, of which 8 were acute respiratory disease syndrome (ARDS) affected (non-COVID-19 ARDS) and 3 were from subjects with non-respiratory diseases (non-COVID-19 non-ARDS) were H&E stained to ascertain histopathological features. Inflammation along the vessel wall was also monitored by expression of NLRP3 and caspase 1. RESULTS: In lungs from COVID-19 affected subjects, vascular changes in the form of microthrombi in small vessels, arterial thrombosis, and organization were extensive as compared to lungs from non-COVID-19 (i.e., non-COVID-19 ARDS and non-COVID-19 non-ARDS) affected subjects. The expression of NLRP3 pathway components was higher in lungs from COVID-19 ARDS subjects as compared to non-COVID-19 non-ARDS cases. No differences were observed between COVID-19 ARDS and non-COVID-19 ARDS lungs. CONCLUSION: Vascular changes as well as NLRP3 inflammasome pathway activation were not different between COVID-19 and non-COVID-19 ARDS suggesting that these responses are not a COVID-19 specific phenomenon and are possibly more related to respiratory distress and associated strategies (such as MV) for treatment. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12931-022-01944-8.
format Online
Article
Text
id pubmed-8830114
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-88301142022-02-11 Pulmonary vascular inflammation with fatal coronavirus disease 2019 (COVID-19): possible role for the NLRP3 inflammasome Paul, Oindrila Tao, Jian Qin West, Eric Litzky, Leslie Feldman, Michael Montone, Kathleen Rajapakse, Chamith Bermudez, Christian Chatterjee, Shampa Respir Res Research BACKGROUND: Pulmonary hyperinflammation is a key event with SARS-CoV-2 infection. Acute respiratory distress syndrome (ARDS) that often accompanies COVID-19 appears to have worse outcomes than ARDS from other causes. To date, numerous lung histological studies in cases of COVID-19 have shown extensive inflammation and injury, but the extent to which these are a COVID-19 specific, or are an ARDS and/or mechanical ventilation (MV) related phenomenon is not clear. Furthermore, while lung hyperinflammation with ARDS (COVID-19 or from other causes) has been well studied, there is scarce documentation of vascular inflammation in COVID-19 lungs. METHODS: Lung sections from 8 COVID-19 affected and 11 non-COVID-19 subjects, of which 8 were acute respiratory disease syndrome (ARDS) affected (non-COVID-19 ARDS) and 3 were from subjects with non-respiratory diseases (non-COVID-19 non-ARDS) were H&E stained to ascertain histopathological features. Inflammation along the vessel wall was also monitored by expression of NLRP3 and caspase 1. RESULTS: In lungs from COVID-19 affected subjects, vascular changes in the form of microthrombi in small vessels, arterial thrombosis, and organization were extensive as compared to lungs from non-COVID-19 (i.e., non-COVID-19 ARDS and non-COVID-19 non-ARDS) affected subjects. The expression of NLRP3 pathway components was higher in lungs from COVID-19 ARDS subjects as compared to non-COVID-19 non-ARDS cases. No differences were observed between COVID-19 ARDS and non-COVID-19 ARDS lungs. CONCLUSION: Vascular changes as well as NLRP3 inflammasome pathway activation were not different between COVID-19 and non-COVID-19 ARDS suggesting that these responses are not a COVID-19 specific phenomenon and are possibly more related to respiratory distress and associated strategies (such as MV) for treatment. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12931-022-01944-8. BioMed Central 2022-02-10 2022 /pmc/articles/PMC8830114/ /pubmed/35144622 http://dx.doi.org/10.1186/s12931-022-01944-8 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Paul, Oindrila
Tao, Jian Qin
West, Eric
Litzky, Leslie
Feldman, Michael
Montone, Kathleen
Rajapakse, Chamith
Bermudez, Christian
Chatterjee, Shampa
Pulmonary vascular inflammation with fatal coronavirus disease 2019 (COVID-19): possible role for the NLRP3 inflammasome
title Pulmonary vascular inflammation with fatal coronavirus disease 2019 (COVID-19): possible role for the NLRP3 inflammasome
title_full Pulmonary vascular inflammation with fatal coronavirus disease 2019 (COVID-19): possible role for the NLRP3 inflammasome
title_fullStr Pulmonary vascular inflammation with fatal coronavirus disease 2019 (COVID-19): possible role for the NLRP3 inflammasome
title_full_unstemmed Pulmonary vascular inflammation with fatal coronavirus disease 2019 (COVID-19): possible role for the NLRP3 inflammasome
title_short Pulmonary vascular inflammation with fatal coronavirus disease 2019 (COVID-19): possible role for the NLRP3 inflammasome
title_sort pulmonary vascular inflammation with fatal coronavirus disease 2019 (covid-19): possible role for the nlrp3 inflammasome
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8830114/
https://www.ncbi.nlm.nih.gov/pubmed/35144622
http://dx.doi.org/10.1186/s12931-022-01944-8
work_keys_str_mv AT pauloindrila pulmonaryvascularinflammationwithfatalcoronavirusdisease2019covid19possibleroleforthenlrp3inflammasome
AT taojianqin pulmonaryvascularinflammationwithfatalcoronavirusdisease2019covid19possibleroleforthenlrp3inflammasome
AT westeric pulmonaryvascularinflammationwithfatalcoronavirusdisease2019covid19possibleroleforthenlrp3inflammasome
AT litzkyleslie pulmonaryvascularinflammationwithfatalcoronavirusdisease2019covid19possibleroleforthenlrp3inflammasome
AT feldmanmichael pulmonaryvascularinflammationwithfatalcoronavirusdisease2019covid19possibleroleforthenlrp3inflammasome
AT montonekathleen pulmonaryvascularinflammationwithfatalcoronavirusdisease2019covid19possibleroleforthenlrp3inflammasome
AT rajapaksechamith pulmonaryvascularinflammationwithfatalcoronavirusdisease2019covid19possibleroleforthenlrp3inflammasome
AT bermudezchristian pulmonaryvascularinflammationwithfatalcoronavirusdisease2019covid19possibleroleforthenlrp3inflammasome
AT chatterjeeshampa pulmonaryvascularinflammationwithfatalcoronavirusdisease2019covid19possibleroleforthenlrp3inflammasome